{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:17:09Z","timestamp":1787995029004,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10067-026-08314-5","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:25:15Z","timestamp":1784784315000},"page":"5759-5767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy and safety of benzbromarone and febuxostat in combined-type hyperuricemia: a single-center study"],"prefix":"10.1007","volume":"45","author":[{"given":"Binbin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxia","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihua","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7747-7788","authenticated-orcid":false,"given":"Lindi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6373-9134","authenticated-orcid":false,"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"31","key":"8314_CR1","doi-asserted-by":"publisher","first-page":"7612","DOI":"10.1080\/10408398.2025.2475238","volume":"65","author":"L Sun","year":"2025","unstructured":"Sun L, Zhang M, Zhao J, Chen W, Wang G (2025) The human gut microbiota and uric acid metabolism: genes, metabolites, and diet. Crit Rev Food Sci Nutr 65(31):7612\u20137632. https:\/\/doi.org\/10.1080\/10408398.2025.2475238","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"12","key":"8314_CR2","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/ard-2023-224679","volume":"82","author":"H Xu","year":"2023","unstructured":"Xu H, Qin H, Hua Y, Dalbeth N (2023) Contributions of joint damage-related events to gout pathogenesis: new insights from laboratory research. Ann Rheum Dis 82(12):1511\u20131515. https:\/\/doi.org\/10.1136\/ard-2023-224679","journal-title":"Ann Rheum Dis"},{"issue":"10287","key":"8314_CR3","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth N, Gosling AL, Gaffo A, Abhishek A (2021) Gout. Lancet 397(10287):1843\u20131855. https:\/\/doi.org\/10.1016\/S0140-6736(21)00569-9","journal-title":"Lancet"},{"issue":"6","key":"8314_CR4","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T et al (2020) 2020 American College of Rheumatology Guideline for the management of gout. Arthritis Care Res (Hoboken) 72(6):744\u2013760. https:\/\/doi.org\/10.1002\/acr.24180","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"8314_CR5","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1007\/s10067-025-07603-9","volume":"44","author":"J Ren","year":"2025","unstructured":"Ren J, Yan X, Zeng S et al (2025) Multiple comorbidities and economic burden of hospitalized gout patients in Guangdong Province. Clin Rheumatol 44(11):4637\u20134645. https:\/\/doi.org\/10.1007\/s10067-025-07603-9","journal-title":"Clin Rheumatol"},{"issue":"7","key":"8314_CR6","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/art.42838","volume":"76","author":"H Qi","year":"2024","unstructured":"Qi H, Sun M, Terkeltaub R et al (2024) Hyperuricemia subtypes classified according to renal uric acid handling manifesting distinct phenotypic and genetic profiles in people with gout. Arthritis Rheumatol 76(7):1130\u20131140. https:\/\/doi.org\/10.1002\/art.42838","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"8314_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/annrheumdis-2019-216644","volume":"79","author":"A Nakayama","year":"2020","unstructured":"Nakayama A, Nakatochi M, Kawamura Y et al (2020) Subtype-specific gout susceptibility loci and enrichment of selection pressure on ABCG2 and ALDH2 identified by subtype genome-wide meta-analyses of clinically defined gout patients. Ann Rheum Dis 79(5):657\u2013665. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216644","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"8314_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/14728222.2018.1420167","volume":"22","author":"K Fujita","year":"2018","unstructured":"Fujita K, Ichida K (2018) ABCG2 as a therapeutic target candidate for gout. Expert Opin Ther Targets 22(2):123\u2013129. https:\/\/doi.org\/10.1080\/14728222.2018.1420167","journal-title":"Expert Opin Ther Targets"},{"key":"8314_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092468","author":"Y Lee","year":"2022","unstructured":"Lee Y, Hwang J, Desai SH et al (2022) Efficacy of xanthine oxidase inhibitors in lowering serum uric acid in chronic kidney disease: a systematic review and meta-analysis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11092468","journal-title":"J Clin Med"},{"issue":"16","key":"8314_CR10","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40265-023-01944-y","volume":"83","author":"R Terkeltaub","year":"2023","unstructured":"Terkeltaub R (2023) Emerging urate-lowering drugs and pharmacologic treatment strategies for gout: a narrative review. Drugs 83(16):1501\u20131521. https:\/\/doi.org\/10.1007\/s40265-023-01944-y","journal-title":"Drugs"},{"issue":"9","key":"8314_CR11","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1093\/ndt\/gfx313","volume":"33","author":"HW Chou","year":"2018","unstructured":"Chou HW, Chiu HT, Tsai CW et al (2018) Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant 33(9):1620\u20131627. https:\/\/doi.org\/10.1093\/ndt\/gfx313","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"8314_CR12","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3760\/cma.j.cn112138-20221027-00796","volume":"62","author":"D Xu","year":"2023","unstructured":"Xu D, Zhu XX, Zou HJ, Lin H, Zhao Y (2023) Guidelines for the diagnosis and treatment of gout [in Chinese]. Chin J Intern Med 62(9):1068\u20131076. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20221027-00796","journal-title":"Chin J Intern Med"},{"issue":"7","key":"8314_CR13","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s10067-022-06110-5","volume":"41","author":"D Liu","year":"2022","unstructured":"Liu D, Zhou B, Li Z et al (2022) Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study. Clin Rheumatol 41(7):2121\u20132128. https:\/\/doi.org\/10.1007\/s10067-022-06110-5","journal-title":"Clin Rheumatol"},{"key":"8314_CR14","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ncomms1756","volume":"3","author":"K Ichida","year":"2012","unstructured":"Ichida K, Matsuo H, Takada T et al (2012) Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 3:764. https:\/\/doi.org\/10.1038\/ncomms1756","journal-title":"Nat Commun"},{"issue":"1","key":"8314_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13075-019-1976-x","volume":"21","author":"N Liang","year":"2019","unstructured":"Liang N, Sun M, Sun R et al (2019) Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort. Arthritis Res Ther 21(1):200. https:\/\/doi.org\/10.1186\/s13075-019-1976-x","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"8314_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/acr.25283","volume":"76","author":"X Xue","year":"2024","unstructured":"Xue X, Sun M, Yan F et al (2024) Superiority of low-dose benzbromarone add-on to low-dose febuxostat compared with febuxostat monotherapy in gout with combined-type hyperuricemia. Arthritis Care Res (Hoboken) 76(5):703\u2013711. https:\/\/doi.org\/10.1002\/acr.25283","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"8314_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114628","volume":"43","author":"J He","year":"2024","unstructured":"He J, Liu G, Kong F et al (2024) Structural basis for the transport and substrate selection of human urate transporter 1. Cell Rep 43(8):114628. https:\/\/doi.org\/10.1016\/j.celrep.2024.114628","journal-title":"Cell Rep"},{"key":"8314_CR18","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/gucdd2020016","volume":"2","author":"T Takada","year":"2024","unstructured":"Takada T, Miyata H, Toyoda Y, Nakayama A, Ichida K, Matsuo H (2024) Regulation of urate homeostasis by membrane transporters. Gout Urate Cryst Depos Dis 2:206\u2013219. https:\/\/doi.org\/10.3390\/gucdd2020016","journal-title":"Gout Urate Cryst Depos Dis"},{"issue":"6","key":"8314_CR19","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1093\/rheumatology\/keaa668","volume":"60","author":"X Xue","year":"2021","unstructured":"Xue X, Liu Z, Li X et al (2021) The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study. Rheumatology (Oxford) 60(6):2661\u20132671. https:\/\/doi.org\/10.1093\/rheumatology\/keaa668","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"8314_CR20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","volume":"56","author":"M Hui","year":"2017","unstructured":"Hui M, Carr A, Cameron S et al (2017) The British Society for Rheumatology Guideline for the management of gout. Rheumatology (Oxford) 56(7):e1\u2013e20. https:\/\/doi.org\/10.1093\/rheumatology\/kex156","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"8314_CR21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/1756-185X.13266","volume":"21","author":"KH Yu","year":"2018","unstructured":"Yu KH, Chen DY, Chen JH et al (2018) Management of gout and hyperuricemia: multidisciplinary consensus in Taiwan. Int J Rheum Dis 21(4):772\u2013787. https:\/\/doi.org\/10.1111\/1756-185X.13266","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"8314_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.70375","volume":"28","author":"M Sun","year":"2025","unstructured":"Sun M, Lyu Z, Wang C et al (2025) 2024 update of Chinese guidelines for diagnosis and treatment of hyperuricemia and gout part I: recommendations for general patients. Int J Rheum Dis 28(7):e70375. https:\/\/doi.org\/10.1111\/1756-185x.70375","journal-title":"Int J Rheum Dis"},{"key":"8314_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152800","volume":"74","author":"S Kohn","year":"2025","unstructured":"Kohn S, Sayles H, Helget LN et al (2025) Real-world persistence of urate-lowering therapy following a treat-to-target intervention: a two-year follow-up analysis of the STOP gout trial. Semin Arthritis Rheum 74:152800. https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152800","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"8314_CR24","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12(2):R63. https:\/\/doi.org\/10.1186\/ar2978","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"8314_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E et al (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209707","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"8314_CR26","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1097\/HJH.0000000000003484","volume":"41","author":"K Kohagura","year":"2023","unstructured":"Kohagura K, Satoh A, Kochi M et al (2023) Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial. J Hypertens 41(9):1420\u20131428. https:\/\/doi.org\/10.1097\/HJH.0000000000003484","journal-title":"J Hypertens"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08314-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08314-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08314-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:34:55Z","timestamp":1787992495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08314-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8314"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08314-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"24 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The study protocol was approved by the Institutional Ethics Committee of Zhongshan Hospital (Xiamen), Fudan University (Approval No. B2026-032).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The requirement for informed consent was waived due to the retrospective design.","order":2,"name":"Ethics","label":"Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. The authors have full control of all primary data and agree to allow the journal to review their data if requested.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}